Funding for this research was provided by:
Medical Research Council (MR/R014973/1)
Department for International Development (MR/R014973/1)
Received: 16 November 2020
Accepted: 22 April 2021
First Online: 30 May 2021
: Ethical approval for the PI consultation group conduct and all material (PI consent form, plain English summary, protocol, agenda, draft FLYBITE volunteer advertisement/volunteer information leaflets) was successfully obtained from the Department of Biology Ethics Committee, University of York (Ethics reference PK201812). Ethical approval from the NHS Research Ethics Committee was not deemed necessary as outlined by the NHS Health Research Authority decision tool and according to INVOLVE guidance. The PI consultation group was carried out prior to any interventional clinical studies and therefore prior to their ethical review.
: All participants consented for audio recording and subsequent results to be analysed and published.
: The authors declare no competing interests. PK and CJL are co-authors of a patent protecting the gene insert used in the leishmaniasis candidate vaccine ChAd63-KH (Europe 10719953.1; India 315101).